Efficacy of oryz-aspergillus enzyme and pancreatin in cirrhotic patients with dyspepsia: a randomized, controlled study
Shan Liang,Zuopeng Fan,Wei Nie,Lixia Qiu,Xinhuan Wei,Lixia Ma,Wei Lin,Yirong Liu,Jing Zhang,Zhongjie Hu
DOI: https://doi.org/10.15932/j.0253-9713.2017.09.002
2017-01-01
Abstract:Objective To evaluate the efficacy and safety of combizym in cirrhotic patients with dyspepsia.Methods This is a prospective,randomized,controlled clinical study.The cirrhotic patients with two or more following symptoms:upper abdominal pain,epigastria burning sensation,postprandial fullness,early satiety,nausea,vomiting,loss of appetite,belching were enrolled.The range of age was 18 to 70 years old and either gender were included.The exclusion criteria included ALT or AST＞200 U/L,T-BIL＞100 μtmol/L;liver failure;massive ascites or abdominal infection;gastrointestinal disease;gastrointestinal bleeding and hepatic encephalopathy Ⅲ stage or more;and other serious complications.Patients were randomly divided into two groups,the control group with regular treatment (rest,liver protective medicine,complication treatment),the treatment group were treated with combizym tablet(2 tablets tid,with a meal or post meal,for 2 weeks) on the basis of regular treatment.The score of dyspeptic symptoms and the safety were assessed respectively at week 1 and week 2 of the trial.Results A total of 166 cirrhotic patients with dyspepsia were enrolled in the study,124 were males and 42 were females,and the average age was (54.9±8.9)years old.Patients were randomly divided into the control group (n=82) and the treatment group (n=84).The baseline data were compared.After 1 week of treatment,the total score of dyspeptic symptoms in both groups declined,and the score in the treatment group (8.8±2.4) was lower than that in the control group (9.6±2.8),but the difference was not statistically significant (P =0.064).After 2 weeks,the scores in both groups further reduced,and the score in the treatment group (5.4±2.1) was significantly lower than that in the control group (8.8±2.6) (P ＜ 0.001).Moreover,the efficacy of combizym on abdominal pain,burning sensation in the upper abdomen,postprandial fullness,early satiety,nausea,vomiting,loss of appetite and belching symptoms was significantlybetter in the treatment group than that in the control group with the effective rates of 61.1％-95.2％ except the symptom ofvomiting.There was no treatment-related adverse drug reactions during the study.Conclusion Combizym is effectiveand safe in the treatment of cirrhotic patients with dyspeptic symptoms.